Ponatinib (AP24534)

For research use only. Not for use in humans.

製品コードS1490

分子量(MW)：532.56

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

サイズ

価格(税別)

在庫

10mM (1mL in DMSO)	JPY 18600	あり
10mg	JPY 20200	あり
50mg	JPY 63400	あり
200mg	JPY 163000	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(83)

製品安全説明書

Bcr-Abl阻害剤の選択性比較

生物活性

製品説明

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

ターゲット

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	もっとクリックする
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	もっとクリックする

体外試験

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

細胞データ

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DFZmlEPTB;MD6wNFAxODByM{W5JO69VQ>?	M1;uZnNCVkeHUh?=
MV-4-11	NXj0T4RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnKTWM2OD1yLkCwNFA6PTZizszN	NUfL[5dOW0GQR1XS
MEG-01	NH7NcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PEOWlEPTB;MD6wNFAyOjhizszN	Mkm0V2FPT0WU
LAMA-84	NH:4SnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;5bpBKSzVyPUCuNFAxOTZ3IN88US=>	M2\1OnNCVkeHUh?=
CGTH-W-1	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMECxOlkh\|ryP	NIrpd4hUSU6JRWK=
KASUMI-1	MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLpbYlvUUN3ME2wMlAxOjF5IN88US=>	NYX4boo4W0GQR1XS
BE-13	NH3kRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMECyOVkh\|ryP	MlLrV2FPT0WU
CTV-1	MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYmxbY1bUUN3ME2wMlAxPTJzIN88US=>	MULTRW5ITVJ?
NKM-1	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLJdVE1UUN3ME2wMlAxPjV3IN88US=>	NYraPWpPW0GQR1XS
MONO-MAC-6	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPOWohKSzVyPUCuNFA5OzdizszN	MVTTRW5ITVJ?
A204	MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoG5TWM2OD1yLkCxNlE5KM7:TR?=	MkjDV2FPT0WU
GDM-1	M3\3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LqTmlEPTB;MD6wNVg{OyEQvF2=	MXnTRW5ITVJ?
AN3-CA	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvUd3RKSzVyPUCuNFE5PzNizszN	M{XjdXNCVkeHUh?=
BL-70	M1vtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMEKxPVkh\|ryP	NYC4ZWlmW0GQR1XS
Daudi	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHpO5FKSzVyPUCuNFI2OzdizszN	MojmV2FPT0WU
KU812	M{DURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMEK4OFgh\|ryP	NXrXem5wW0GQR1XS
KG-1	MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnJTWM2OD1yLkCzNlk1KM7:TR?=	MkDjV2FPT0WU
DOHH-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGP3dndKSzVyPUCuNFQ5ODNizszN	NIWzU49USU6JRWK=
HuO9	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXG2NWVSUUN3ME2wMlA2PDR6IN88US=>	NX;B[XhpW0GQR1XS
EB2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHa[W1QUUN3ME2wMlA2PTd4IN88US=>	MlXxV2FPT0WU
G-402	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrTTWM2OD1yLkC2N\|QyKM7:TR?=	NX60dplsW0GQR1XS
SU-DHL-1	NFezbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:xV3RGUUN3ME2wMlA3Ozd7IN88US=>	MojtV2FPT0WU
NCI-H719	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkS1TWM2OD1yLkC3PFg5KM7:TR?=	MX3TRW5ITVJ?
MLMA	M1LjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwMEmwOkDPxE1?	MWHTRW5ITVJ?
KM12	NIGyTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEm3N\|ch\|ryP	NXfuNZNZW0GQR1XS
SUP-T1	NFX3[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXuTWM2OD1yLkC5PVgzKM7:TR?=	NH3aVJhUSU6JRWK=
MZ1-PC	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHn0dmJKSzVyPUCuNVE{OzZizszN	M33Fb3NCVkeHUh?=
MFE-296	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnm2TWM2OD1yLkGxPFM6KM7:TR?=	NEjaNZhUSU6JRWK=
ALL-PO	M2HwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMUK0OFMh\|ryP	MnXMV2FPT0WU
GB-1	NWPU[JFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPNOXVKSzVyPUCuNVI2OTJizszN	MnzZV2FPT0WU
SIG-M5	M1;QTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\XbGlEPTB;MD6xN\|M4KM7:TR?=	NXvtbno{W0GQR1XS
P30-OHK	NGT5WXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXBTWM2OD1yLkG1OlczKM7:TR?=	M3nIVHNCVkeHUh?=
NCI-H716	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\hZmpKSzVyPUCuNVYzPjZizszN	NI\yVphUSU6JRWK=
MPP-89	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMU[5N\|Mh\|ryP	NHPBeWNUSU6JRWK=
SF126	M3uyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXMO3JKSzVyPUCuNVcxPjNizszN	NHPsZWpUSU6JRWK=
CTB-1	MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrETWM2OD1yLkG3N\|E3KM7:TR?=	MlvEV2FPT0WU
CA46	NV\4Nml7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33GfWlEPTB;MD6xO\|Q5QSEQvF2=	MmHhV2FPT0WU
NCI-H520	NIr3b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUj2[I1rUUN3ME2wMlE4PzN{IN88US=>	MmGyV2FPT0WU
CAL-85-1	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWO3XWgxUUN3ME2wMlE4QTJ5IN88US=>	NIPVbphUSU6JRWK=
NCI-H2342	M2jIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYS3NmY2UUN3ME2wMlE5PTd5IN88US=>	MofjV2FPT0WU
697	M1XiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEW1b5pKSzVyPUCuNVg5PzFizszN	MWnTRW5ITVJ?
NY	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PCdGlEPTB;MD6xPVI5PyEQvF2=	M1jUd3NCVkeHUh?=
T98G	NIfCSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vMW2lEPTB;MD6xPVMyQCEQvF2=	NGLoTWVUSU6JRWK=
NCI-H1703	NWL3VINLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nwcWlEPTB;MD6xPVYyPSEQvF2=	Mn;qV2FPT0WU
NCI-H2087	NWDPd3ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1KxZ2lEPTB;MD6yNFQ{QSEQvF2=	MU\TRW5ITVJ?
PF-382	M1PVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHleIVrUUN3ME2wMlIxQDd\|IN88US=>	Mo\vV2FPT0WU
HCT-116	NFzNZ\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELvWWJKSzVyPUCuNlExPjlizszN	MUTTRW5ITVJ?
CAKI-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DRcWlEPTB;MD6yNVY3PiEQvF2=	Ml3iV2FPT0WU
CCF-STTG1	MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PsTGlEPTB;MD6yNlQ4PSEQvF2=	NITxZYJUSU6JRWK=
D-392MG	M3LPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTp[2hRUUN3ME2wMlI{OTd5IN88US=>	Mn7QV2FPT0WU
RT-112	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMkO3PVUh\|ryP	NITuRlZUSU6JRWK=
MES-SA	MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYL6PYQ4UUN3ME2wMlI1OTh5IN88US=>	NVPSN\|FHW0GQR1XS
LC-2-ad	NEK0TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:wWWlEPTB;MD6yOFI3PSEQvF2=	NXvwRoNtW0GQR1XS
NOS-1	NXfleYtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;mcmlEPTB;MD6yOFM3PyEQvF2=	NIX4UJVUSU6JRWK=
NALM-6	M1zBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPWT\|ZKSzVyPUCuNlU2PDNizszN	MkPqV2FPT0WU
TE-15	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMk[wPVEh\|ryP	MUTTRW5ITVJ?
786-0	NYrtTYZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fZcmlEPTB;MD6yOlIzQCEQvF2=	MVvTRW5ITVJ?
IST-MES1	NWKycZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMk[4Nlkh\|ryP	M3rZVXNCVkeHUh?=
KYSE-180	NXLpVnFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPqPG91UUN3ME2wMlI3QDlzIN88US=>	NG\iTGVUSU6JRWK=
YT	MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMk[5O\|Qh\|ryP	MVnTRW5ITVJ?
A427	NUnS[\|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LHTWlEPTB;MD6yO\|I3PCEQvF2=	Mn34V2FPT0WU
KYSE-450	NHX1bldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWS4fo5uUUN3ME2wMlI4OzJ7IN88US=>	MUnTRW5ITVJ?
HuH-7	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwMke3OlMh\|ryP	MULTRW5ITVJ?
CAS-1	NIrL[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPGSYRKSzVyPUCuNlg{ODNizszN	MXnTRW5ITVJ?
KURAMOCHI	NYq0VlFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojKTWM2OD1yLkK4OFE6KM7:TR?=	MYLTRW5ITVJ?
ACHN	M4TVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnZTWM2OD1yLkK5N\|I{KM7:TR?=	NFnybIZUSU6JRWK=
HGC-27	NVHhbnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMkmzOVMh\|ryP	Mo\RV2FPT0WU
A172	Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DjZWlEPTB;MD6yPVU4PyEQvF2=	MUfTRW5ITVJ?
SNU-449	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfTc3VKSzVyPUCuNlk6PjRizszN	MVrTRW5ITVJ?
SW982	NULIOo92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMkm5O\|gh\|ryP	MkLoV2FPT0WU
EFO-21	NFjTR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETZRppKSzVyPUCuN\|A1OTFizszN	NVnN[\|M1W0GQR1XS
NCI-H2030	NFS4NHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwM{GxOlQh\|ryP	NYXMc4RvW0GQR1XS
HT-144	NYOwS4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPxTWM2OD1yLkOxNlgh\|ryP	M2HT[HNCVkeHUh?=
MFE-280	NGj1OYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvn[XFKSzVyPUCuN\|E1PTNizszN	MkTRV2FPT0WU
SK-LU-1	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwM{G0OlYh\|ryP	M17ZdHNCVkeHUh?=
NCI-H2052	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXqOGZrUUN3ME2wMlMyPDh2IN88US=>	M4W1cHNCVkeHUh?=
SK-HEP-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvQVm1KSzVyPUCuN\|M{PjhizszN	MnTpV2FPT0WU
QIMR-WIL	NG\lO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPhTWM2OD1yLkOzOFI1KM7:TR?=	NVj4dJpuW0GQR1XS
A2780	NV;uT\|dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwM{SzNFQh\|ryP	MX\TRW5ITVJ?
ACN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33ZZWlEPTB;MD6zOFg4OyEQvF2=	MXXTRW5ITVJ?
BxPC-3	NX[xdXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHqOHY2UUN3ME2wMlM1QTh7IN88US=>	M3vNTHNCVkeHUh?=
BCPAP	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTLTWM2OD1yLkO2NFAyKM7:TR?=	NY\adnB5W0GQR1XS
HOP-62	M3Xzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLLZZBjUUN3ME2wMlM3OTB4IN88US=>	M1v2N3NCVkeHUh?=
SW1710	Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moe1TWM2OD1yLkO2OFU2KM7:TR?=	NHHaTXFUSU6JRWK=
OPM-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUH5dJpXUUN3ME2wMlM3PDd\|IN88US=>	MWrTRW5ITVJ?
DBTRG-05MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjkTWM2OD1yLkO4NFU1KM7:TR?=	NETaXodUSU6JRWK=
SK-MEL-24	M{fsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwM{m3PVEh\|ryP	NHrqfWlUSU6JRWK=
8305C	M{nZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2e4dmlEPTB;MD6zPVc6OyEQvF2=	MX\TRW5ITVJ?
OVCAR-4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vIXGlEPTB;MD60NVU5PiEQvF2=	NUnrSFM6W0GQR1XS
HLE	NVK0ZmxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjySoZKSzVyPUCuOFE5PiEQvF2=	MWfTRW5ITVJ?
NCI-H747	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHrTVlKSzVyPUCuOFIyOzdizszN	MXrTRW5ITVJ?
SW780	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrJTWM2OD1yLkSyN\|Q3KM7:TR?=	NXPo[2tIW0GQR1XS
KYSE-150	NIHabHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnpXW5SUUN3ME2wMlQzPDF3IN88US=>	Mn3iV2FPT0WU
H4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33RPGlEPTB;MD60NlQ2OSEQvF2=	MXXTRW5ITVJ?
SW1088	M3X2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPXTWM2OD1yLkS0N\|kh\|ryP	MkP5V2FPT0WU
SF268	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwNES4OkDPxE1?	MWXTRW5ITVJ?
RT4	M4fyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLOTWM2OD1yLkS1NVEyKM7:TR?=	NEXKU3RUSU6JRWK=
NCI-H522	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFe4ZlFKSzVyPUCuOFUzPyEQvF2=	MWfTRW5ITVJ?
LCLC-97TM1	NV\TWXA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIC3OlJKSzVyPUCuOFYyQTVizszN	M{fOUnNCVkeHUh?=
CAL-39	M1XwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXG[mQ1UUN3ME2wMlQ3PTF7IN88US=>	MlL0V2FPT0WU
CAL-120	MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwNEe2OFMh\|ryP	MmnsV2FPT0WU
ESS-1	Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M120ZWlEPTB;MD60O\|gzOSEQvF2=	NVLDTFVxW0GQR1XS
KARPAS-45	NYPaTVhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fRSGlEPTB;MD60PFk{OyEQvF2=	MYPTRW5ITVJ?
DU-4475	NEi1OXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwNEm1NVEh\|ryP	MXvTRW5ITVJ?
VMRC-RCZ	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwNEm5NFQh\|ryP	NEjPcoJUSU6JRWK=
HOS	M1rYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXRUYZ{UUN3ME2wMlUxOzZ3IN88US=>	M3roW3NCVkeHUh?=
MOLT-16	NWnPZXQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIKySXJKSzVyPUCuOVE5ODhizszN	MWTTRW5ITVJ?
RPMI-6666	NVzhemZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXTeZo5UUN3ME2wMlUzOTN3IN88US=>	M4HjUHNCVkeHUh?=
K052	MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwNUKxOEDPxE1?	M3TXSHNCVkeHUh?=
EHEB	NWPlVHFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHhbJRKSzVyPUCuOVIyQDJizszN	Ml7yV2FPT0WU
MFH-ino	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPOTWM2OD1yLkWyN\|UyKM7:TR?=	MlnCV2FPT0WU
A4-Fuk	MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTyTWM2OD1yLkWyOVI5KM7:TR?=	MWXTRW5ITVJ?
SW1417	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnaTWM2OD1yLkWyO\|gyKM7:TR?=	Mki4V2FPT0WU
DoTc2-4510	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInVZ3NKSzVyPUCuOVQ6PThizszN	M2LIW3NCVkeHUh?=
TE-12	Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfKU3ZKSzVyPUCuOVU4OzVizszN	NWrHV2FsW0GQR1XS
8-MG-BA	M17OSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlraTWM2OD1yLkW2NFU3KM7:TR?=	NUL5dZVjW0GQR1XS
ECC12	M2LjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwNU[1OVgh\|ryP	MnLDV2FPT0WU
CHL-1	NFrjXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz5doJGUUN3ME2wMlU4PDZ\|IN88US=>	M1qzc3NCVkeHUh?=
LCLC-103H	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;1VppKSzVyPUCuOVg{PDRizszN	M1LQOHNCVkeHUh?=
OS-RC-2	NH7hWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fMUmlEPTB;MD61PFM4QSEQvF2=	NFTsXGhUSU6JRWK=
RO82-W-1	NWrrR\|dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHHPJZKSzVyPUCuOVk3OTVizszN	NWTEc5NqW0GQR1XS
A3-KAW	NV3aXodkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwNkG0Olch\|ryP	MXPTRW5ITVJ?
NCCIT	NULFV2MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPvRVRKSzVyPUCuOlE4OTVizszN	M1e5UXNCVkeHUh?=
IST-SL2	M{SydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHpVoxKSzVyPUCuOlI2OjJizszN	NVz2dGV4W0GQR1XS
GI-ME-N	NH7hUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwNkOwOlkh\|ryP	NWPWZYxVW0GQR1XS
ES6	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jlfWlEPTB;MD62N\|I6PSEQvF2=	NI\HXoxUSU6JRWK=
BL-41	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\3TWM2OD1yLk[zN\|UzKM7:TR?=	NVPyeIs2W0GQR1XS
Ca-Ski	MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjHTWM2OD1yLk[0PFEh\|ryP	NGHqSHZUSU6JRWK=
HOP-92	NGDOfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzHTWM2OD1yLk[1OlczKM7:TR?=	NYDGTpNrW0GQR1XS
SK-LMS-1	NX3OVoV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LvdGlEPTB;MD62OlQ4KM7:TR?=	NGXiOmRUSU6JRWK=
EW-13	M4TK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwNk[3O\|kh\|ryP	NIHHbYlUSU6JRWK=
647-V	NX7Kc2tIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvxTWM2OD1yLk[4NVQ5KM7:TR?=	M3rrRXNCVkeHUh?=
JiyoyeP-2003	Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zNeGlEPTB;MD62PVc{QCEQvF2=	Ml36V2FPT0WU
WSU-NHL	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXocHhiUUN3ME2wMlcxQDh5IN88US=>	MV;TRW5ITVJ?
U-698-M	M1PFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW[1cZc5UUN3ME2wMlcyODZ\|IN88US=>	NYXQVWE2W0GQR1XS
HC-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVniNllOUUN3ME2wMlczPDB3IN88US=>	NVHjPXlDW0GQR1XS
8505C	NFntNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\6W2lEPTB;MD63Nlc1OSEQvF2=	M3LLVXNCVkeHUh?=
HUTU-80	NWHuN5lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFf4TVBKSzVyPUCuO\|M{PDlizszN	M{XQU3NCVkeHUh?=
LB1047-RCC	NIq3cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDtWHlHUUN3ME2wMlc{PTN6IN88US=>	NELwO2xUSU6JRWK=
GAMG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjwWW94UUN3ME2wMlc{PjV\|IN88US=>	MXHTRW5ITVJ?
CAL-12T	MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwN{O4O\|ch\|ryP	MlTMV2FPT0WU
NCI-SNU-1	NYHHZYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGSzT\|VKSzVyPUCuO\|czPzhizszN	NGHlTnNUSU6JRWK=
HTC-C3	NVX3cIpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnoTWM2OD1yLke3OFUyKM7:TR?=	MV3TRW5ITVJ?
HPAF-II	NX\IfIFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzGTWlCUUN3ME2wMlc4PTBzIN88US=>	MYHTRW5ITVJ?
KGN	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwN{iwPFEh\|ryP	MmHnV2FPT0WU
EFO-27	NH62S\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwN{i3N\|Mh\|ryP	Mn:0V2FPT0WU
MEL-HO	M1vXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwN{m0OFkh\|ryP	NHXmUZVUSU6JRWK=
KYSE-270	NGHZZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13sV2lEPTB;MD64NFUzQSEQvF2=	M371Z3NCVkeHUh?=
NCI-H1755	NH3zTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXPZ4dWUUN3ME2wMlgxPzF2IN88US=>	M{LsOXNCVkeHUh?=
MFM-223	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PjeWlEPTB;MD64NVQxPyEQvF2=	MVTTRW5ITVJ?
G-361	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\WTWM2OD1yLkixPFk4KM7:TR?=	M1q3eHNCVkeHUh?=
ETK-1	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fn[2lEPTB;MD64NlQ1OSEQvF2=	MlyzV2FPT0WU
LU-99A	NWDibGRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDGOllrUUN3ME2wMlg1PzBzIN88US=>	NIjibHhUSU6JRWK=
IST-MEL1	NVXN[Xp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHDTWM2OD1yLki1O\|MzKM7:TR?=	MUPTRW5ITVJ?
L-540	NFTP[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFziVnFKSzVyPUCuPFU5ODFizszN	NUfITZZSW0GQR1XS
U-2-OS	NHP0RXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwOEW4OFYh\|ryP	MYrTRW5ITVJ?
HT-1376	NIP5XVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGOxV3NKSzVyPUCuPFYxPTFizszN	NV\nWZZoW0GQR1XS
COLO-680N	NETwRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HreWlEPTB;MD64O\|k{OyEQvF2=	M4fvfnNCVkeHUh?=
NCI-H1581	MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\oN5B2UUN3ME2wMlg6Ojl5IN88US=>	M1vQO3NCVkeHUh?=
HuCCT1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwOEm1OFgh\|ryP	MUTTRW5ITVJ?
BB30-HNC	M2\OW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXqxO4pnUUN3ME2wMlkzPDZ7IN88US=>	Ml;JV2FPT0WU
NCI-H2347	NID2[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjxPIdnUUN3ME2wMlk{Ojl{IN88US=>	NWizbYo{W0GQR1XS
G-401	MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwOUO2PVUh\|ryP	NXzqRZN7W0GQR1XS
NCI-H358	NX\xUW92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ji[GlEPTB;MD65OVAyPCEQvF2=	NXTvSplVW0GQR1XS
HCC1395	MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwOUW0OlEh\|ryP	NInZb5dUSU6JRWK=
J82	M2DNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfVTWM2OD1yLkm1OVQ{KM7:TR?=	M4jzTXNCVkeHUh?=
KE-37	NIroVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jtcmlEPTB;MD65OlM5PyEQvF2=	NETXRWxUSU6JRWK=
NOMO-1	MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnq1TWM2OD1yLkm2OVY1KM7:TR?=	MWrTRW5ITVJ?
ML-2	M2DwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:yfJF5UUN3ME2wMlk6PzVizszN	MWDTRW5ITVJ?
SW872	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwOUm3O\|Uh\|ryP	M{LhenNCVkeHUh?=
KYSE-520	NWTrWZVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjVTWM2OD1zLkCwOFk1KM7:TR?=	MnPsV2FPT0WU
HL-60	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXn6PXNiUUN3ME2xMlAxQTdizszN	M1njeHNCVkeHUh?=
HDLM-2	MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDyN3VKSzVyPUGuNFEzPTJizszN	M{D2TXNCVkeHUh?=
MIA-PaCa-2	MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTFwMEGzO\|Uh\|ryP	NEPw[XFUSU6JRWK=
TCCSUP	NWH4SVVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX60bYJIUUN3ME2xMlAyPzN{IN88US=>	Mn7TV2FPT0WU
SH-4	NH;DWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTrPGZ{UUN3ME2xMlAzOjR2IN88US=>	M1vl[3NCVkeHUh?=
MG-63	M3vOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPpRnhKSzVyPUGuNFI3OTZizszN	NWL6N4hiW0GQR1XS
NB6	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTFwMEOxNFkh\|ryP	MkXlV2FPT0WU
CAL-54	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEH5dZlKSzVyPUGuNFM6PTlizszN	NWfwSVJXW0GQR1XS
DU-145	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTwfYpKSzVyPUGuNFgxPzNizszN	Mo\pV2FPT0WU
HCE-4	NEGxSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe3[GJKSzVyPUGuNFkzQDZizszN	M4S1WnNCVkeHUh?=
U-266	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjLS5JiUUN3ME2xMlA6PjN\|IN88US=>	MnPnV2FPT0WU
HT-1197	NXnGcnlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjTTWM2OD1zLkGxOFM5KM7:TR?=	MUnTRW5ITVJ?
EW-1	NUjUN2NUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTFwMUSxNlgh\|ryP	M2TObHNCVkeHUh?=
MHH-NB-11	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jJeWlEPTB;MT6xOVM3QCEQvF2=	MUTTRW5ITVJ?
NCI-H2405	NVXmeFI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\zZnljUUN3ME2xMlE3OTZizszN	NYWzPGU2W0GQR1XS
COLO-668	M{PpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoraTWM2OD1zLkG2OFkh\|ryP	MYfTRW5ITVJ?
IMR-5	M{[yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LZTGlEPTB;MT6xOlk{PiEQvF2=	MYrTRW5ITVJ?
ARH-77	NXfYPIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NID5WnZKSzVyPUGuNlI6OjRizszN	MkLyV2FPT0WU
BHT-101	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTFwMkO0PUDPxE1?	NGnl[5ZUSU6JRWK=
SCC-25	M17y[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDvTWM2OD1zLkKzOVM3KM7:TR?=	NV3iUlh2W0GQR1XS
NTERA-S-cl-D1	M4Hsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HSVWlEPTB;MT6yOFM1PiEQvF2=	M{Pxd3NCVkeHUh?=
MKN28	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrneFV3UUN3ME2xMlI2PjN4IN88US=>	M4fHbHNCVkeHUh?=
KS-1	M2L5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTFwMkiyOlkh\|ryP	MlrPV2FPT0WU
NCI-H1734	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XnUWlEPTB;MT6yPFkyOyEQvF2=	Ml62V2FPT0WU
ES7	M3;IW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3XTWM2OD1zLkK5OVQzKM7:TR?=	M3XXZXNCVkeHUh?=
NCI-H838	M{n4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1G1NmlEPTB;MT6zNFYyPSEQvF2=	MULTRW5ITVJ?
HEC-1	MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjGVHVKSzVyPUGuN\|M4PTVizszN	MVvTRW5ITVJ?
ME-180	NYDDXpZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnv1TWM2OD1zLkO3PVk{KM7:TR?=	NFToXZRUSU6JRWK=
MMAC-SF	NVGx[2NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\3R4JYUUN3ME2xMlM6PTl3IN88US=>	MX;TRW5ITVJ?
IA-LM	NV;HU2RoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;wXFhVUUN3ME2xMlQxQTF2IN88US=>	M13sVHNCVkeHUh?=
MN-60	NH\he5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fGRWlEPTB;MT60N\|EyPCEQvF2=	M1zONnNCVkeHUh?=
SIMA	NUfBT4VkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPsTWM2OD1zLkS4Olg4KM7:TR?=	M1LFS3NCVkeHUh?=
NCI-H1770	M3Sw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFwNUKwOVQh\|ryP	NYX4VZpOW0GQR1XS
ONS-76	M4O4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLhTWM2OD1zLkWyN\|EyKM7:TR?=	NV\MfG1FW0GQR1XS
LB771-HNC	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nLfmlEPTB;MT61N\|kxPiEQvF2=	M4TGVnNCVkeHUh?=
SW48	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DITGlEPTB;MT61OFI1OyEQvF2=	M1LRNXNCVkeHUh?=
KYSE-140	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XFOmlEPTB;MT61OVc1OSEQvF2=	NELmZmxUSU6JRWK=
SW626	M3HFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVG3ZWc2UUN3ME2xMlU5OTZizszN	NI[1N2FUSU6JRWK=
MC-CAR	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTFwNUi2OlMh\|ryP	NILjW\|ZUSU6JRWK=
D-336MG	NWHzPWpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVKyc\|ZbUUN3ME2xMlYzQTRizszN	Mn3UV2FPT0WU
SK-MEL-3	NWDTRldwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mki0TWM2OD1zLk[zPVAzKM7:TR?=	MoDiV2FPT0WU
MHH-PREB-1	M2jhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTFwNkS0O\|Mh\|ryP	NF;p[nhUSU6JRWK=
Calu-1	NXGxT\|JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jzWmlEPTB;MT62OVM5PiEQvF2=	MkWwV2FPT0WU
HCC1806	NX7vSpdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTm[3JKSzVyPUGuOlY3OTFizszN	MXrTRW5ITVJ?
A101D	NFy0[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIro[IlKSzVyPUGuOlY4QDFizszN	NEPrcmJUSU6JRWK=
A704	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTFwNkizNVEh\|ryP	NWf0fm9RW0GQR1XS
LB831-BLC	M{PI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkK1TWM2OD1zLk[5PFU1KM7:TR?=	M3fubnNCVkeHUh?=
RL95-2	M4ruUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvtTWM2OD1zLkexOFY{KM7:TR?=	MX;TRW5ITVJ?
RPMI-2650	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrUTWM2OD1zLkeyO\|E6KM7:TR?=	NU\qTVk4W0GQR1XS
NH-12	M4LSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTFwN{O0Nlch\|ryP	Mn\5V2FPT0WU
AGS	M3T2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfh[3hKSzVyPUGuO\|Y{PThizszN	M{jGcnNCVkeHUh?=
NEC8	NY\5[XEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjlTWM2OD1zLke4PVk2KM7:TR?=	NFrpXY1USU6JRWK=
NCI-H2009	NIH6UmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvJSGZKSzVyPUGuO\|k4OjFizszN	MVfTRW5ITVJ?
A498	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvtTWVmUUN3ME2xMlgyOjh{IN88US=>	MofXV2FPT0WU
NCI-H810	NFHmfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjWR2x[UUN3ME2xMlgyPjB4IN88US=>	MX3TRW5ITVJ?
SK-NEP-1	NETqWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrCTWM2OD1zLkizO\|Y4KM7:TR?=	M1qyO3NCVkeHUh?=
D-542MG	NGPOemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDNTWM2OD1zLki1PFUyKM7:TR?=	MXXTRW5ITVJ?
KNS-42	M4Ppd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTtVWlKSzVyPUGuPFYzPjZizszN	NInVNoFUSU6JRWK=
NCI-H2452	NG\ucZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTFwOEmwO\|Qh\|ryP	NGPn[VhUSU6JRWK=
SK-MEL-2	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTFwOUCyO\|Eh\|ryP	M13QdHNCVkeHUh?=
OVCAR-5	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\LdlFKSzVyPUGuPVA3PzVizszN	Mn3iV2FPT0WU
SNG-M	NF7mXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWn3Z5ZSUUN3ME2xMlk2QDV6IN88US=>	NFHwN\|lUSU6JRWK=
A673	M1HaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLPUnFJUUN3ME2xMlk4PTF4IN88US=>	NHf0[IJUSU6JRWK=
L-428	NG[yVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vafGlEPTB;MT65PVE4QSEQvF2=	M1joeXNCVkeHUh?=
KM-H2	M2TpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHNTWM2OD1{LkCxNFkh\|ryP	NIXnbIdUSU6JRWK=
MC-IXC	M2D4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTJwMEKyO\|Mh\|ryP	MkHCV2FPT0WU
COLO-678	MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLnTWM2OD1{LkC0NlA4KM7:TR?=	M2e2ZXNCVkeHUh?=
MEL-JUSO	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHjS3gxUUN3ME2yMlA4QDVzIN88US=>	M2LLO3NCVkeHUh?=
HCC38	NWfke2d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJwMEi0N\|Mh\|ryP	NITPXoFUSU6JRWK=
UACC-62	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTJwMEi4OVUh\|ryP	NEe3VFdUSU6JRWK=
OAW-42	MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3H3RmlEPTB;Mj6wPVcyOSEQvF2=	NFG2c4dUSU6JRWK=
LB996-RCC	NVnOZYE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33iO2lEPTB;Mj6xN\|gyPyEQvF2=	MYXTRW5ITVJ?
COR-L105	NGLYeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfUT3hKSzVyPUKuNVY{PzNizszN	MmHoV2FPT0WU
RCC10RGB	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfsd5A2UUN3ME2yMlE5PTd4IN88US=>	M4nyWnNCVkeHUh?=
A431	M1LpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TD[2lEPTB;Mj6xPVAyQSEQvF2=	MYHTRW5ITVJ?
NCI-H292	NHP4NZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\xN5BKSzVyPUKuNlM6PTFizszN	NV[1boVMW0GQR1XS
SK-UT-1	NYfj[2VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTOTWM2OD1{LkOzNVg1KM7:TR?=	NX:wOW1tW0GQR1XS
PANC-08-13	NXqyOIxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1GwOGlEPTB;Mj6zN\|I{PSEQvF2=	MYPTRW5ITVJ?
ST486	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2e0bWlEPTB;Mj60NVA1QCEQvF2=	MUfTRW5ITVJ?
SJSA-1	MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlWxTWM2OD1{LkSxNlcyKM7:TR?=	NIHjb\|dUSU6JRWK=
RKO	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7vPVRKSzVyPUKuOFIxOjlizszN	NVnFZXJMW0GQR1XS
NCI-H1793	M{C2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTJwNESwNlkh\|ryP	NFLUVHVUSU6JRWK=
639-V	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrHTFZ7UUN3ME2yMlQ2Ozh{IN88US=>	MVHTRW5ITVJ?
ES3	M1XRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTJwNEm3N\|ch\|ryP	NIjMcGFUSU6JRWK=
NCI-H1792	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHDTWM2OD1{LkW2PFI3KM7:TR?=	NHvZb2tUSU6JRWK=
NCI-H1651	NX;3S2FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvrVWNKSzVyPUKuOVgzOSEQvF2=	MnzkV2FPT0WU
SN12C	NV:0[2tbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\3UW9KSzVyPUKuOVg1QDdizszN	MojpV2FPT0WU
COLO-679	NH:zb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTKTJdKSzVyPUKuOVg3ODVizszN	M{TpXXNCVkeHUh?=
U-118-MG	NE\lW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTJwNUi4O\|Ih\|ryP	NXKzZoZ4W0GQR1XS
Ramos-2G6-4C10	NXL3T4RCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1H4NGlEPTB;Mj62OFgxPyEQvF2=	NEnDcYpUSU6JRWK=
HCT-15	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIW5SpVKSzVyPUKuOlg4QTJizszN	MmjCV2FPT0WU
MDA-MB-157	NFPOXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{n0PGlEPTB;Mj63NFc1PyEQvF2=	M2\RSnNCVkeHUh?=
K5	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjvUGd5UUN3ME2yMlcyQDR3IN88US=>	MoXaV2FPT0WU
MKN45	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;s[pFRUUN3ME2yMlc{OzZ4IN88US=>	M{LBd3NCVkeHUh?=
DMS-273	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPHRppoUUN3ME2yMlc2PjN{IN88US=>	MYPTRW5ITVJ?
C8166	M4XXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PpSGlEPTB;Mj63PFUyOyEQvF2=	NFW2WWFUSU6JRWK=
Calu-3	M13ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTJwN{i5Olkh\|ryP	NYrUU2ZDW0GQR1XS
SNB75	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTpTWM2OD1{Lki4OVM2KM7:TR?=	MVHTRW5ITVJ?
BFTC-905	NUP6OVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4WzOmlEPTB;Mj65NFE6OSEQvF2=	MluwV2FPT0WU
C-4-II	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HsVmlEPTB;Mj65NVM2OyEQvF2=	MVrTRW5ITVJ?
MS-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXX0eHU4UUN3ME2yMlk3PzZ7IN88US=>	Mm\EV2FPT0WU
A375	NXXHd494T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPkXnByUUN3ME2zMlA5OTh2IN88US=>	NETy[5pUSU6JRWK=
KYSE-70	NHHzSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHX2NItKSzVyPUOuNFg5QDJizszN	MUDTRW5ITVJ?
KYSE-510	M{PPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu2TWM2OD1\|LkGwPVk2KM7:TR?=	MX\TRW5ITVJ?
LN-405	NVvYbGNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vtVWlEPTB;Mz6xN\|UyQCEQvF2=	M{nRV3NCVkeHUh?=
BOKU	MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn65TWM2OD1\|LkG0NlU3KM7:TR?=	M133[nNCVkeHUh?=
TE-10	M4LjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3tVGhKSzVyPUOuNVc{PjJizszN	M{Hmc3NCVkeHUh?=
MKN1	M3ewS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknPTWM2OD1\|LkG4OFg{KM7:TR?=	NWXHN5I4W0GQR1XS
M059J	NYnhS2JnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTNwMkCxO\|Mh\|ryP	MWHTRW5ITVJ?
GOTO	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\rW3UxUUN3ME2zMlIzODN7IN88US=>	M3;1bHNCVkeHUh?=
DK-MG	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTBTWM2OD1\|LkK1PVc3KM7:TR?=	MVnTRW5ITVJ?
NCI-H727	M{HP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHDW5N3UUN3ME2zMlI3PThizszN	MYfTRW5ITVJ?
NB12	M2TMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTNwM{OyNlQh\|ryP	M{CxTXNCVkeHUh?=
DOK	NWjSU2lDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjRUId{UUN3ME2zMlM3OTh4IN88US=>	MmXXV2FPT0WU
KYSE-410	NVfEXFZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvLTWM2OD1\|LkO2Nlg4KM7:TR?=	M4DicXNCVkeHUh?=
AM-38	NUHudJI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXqd3BUUUN3ME2zMlM5ODVzIN88US=>	MXfTRW5ITVJ?
GR-ST	NXTEc\|AxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTZc\|U5UUN3ME2zMlQ2PzN{IN88US=>	MojuV2FPT0WU
D-247MG	NF\4TWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfFR4JFUUN3ME2zMlQ5OjZ\|IN88US=>	M2nCbHNCVkeHUh?=
TE-8	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfRTHNKSzVyPUOuOFk{OzNizszN	M3jVTXNCVkeHUh?=
LS-411N	M4WxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPiNmpKSzVyPUOuOFk3QTJizszN	NIPTZnRUSU6JRWK=
SK-MES-1	MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LsdWlEPTB;Mz61OlQ{OyEQvF2=	NUDoOVRyW0GQR1XS
SF295	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjmXlV{UUN3ME2zMlYyPTV{IN88US=>	NITtVHlUSU6JRWK=
SK-MEL-30	M3XheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTiTWM2OD1\|Lk[1PVIyKM7:TR?=	MkC5V2FPT0WU
LB2241-RCC	MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIi1XldKSzVyPUOuOlYzPiEQvF2=	NYPBO5Q6W0GQR1XS
PC-14	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2KxbmlEPTB;Mz62OlQ{PyEQvF2=	M1f5ZXNCVkeHUh?=
EW-7	M3TvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DSd2lEPTB;Mz62O\|Y6OyEQvF2=	NH[0fYhUSU6JRWK=
NMC-G1	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTNwN{G4N\|ch\|ryP	MWXTRW5ITVJ?
TE-441-T	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[yZ5hKSzVyPUOuO\|MxOjhizszN	Mof5V2FPT0WU
NCI-H1618	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7tTWM2OD1\|LkixPFc2KM7:TR?=	Mo[5V2FPT0WU
PANC-03-27	NVvye5JnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUK1Rnp5UUN3ME2zMlgyQTF4IN88US=>	M3vDe3NCVkeHUh?=
NCI-H2228	Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;0OXJKSzVyPUOuPFMyOjZizszN	NGfYWFFUSU6JRWK=
CAPAN-1	NEfaRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTNwOEewNFkh\|ryP	NGDhZ45USU6JRWK=
KLE	M2X5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTNwOUC2O{DPxE1?	MWDTRW5ITVJ?
Becker	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LvRWlEPTB;Mz65Nlg1QSEQvF2=	M4\KSXNCVkeHUh?=
SK-PN-DW	NXvhNFNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYWzemoyUUN3ME20MlA4QTd2IN88US=>	NVq3RlhFW0GQR1XS
Hs-578-T	NEXOfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HSSGlEPTB;ND6wPFMxPiEQvF2=	NGnzPJpUSU6JRWK=
RS4-11	M1vzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfiSWhKSzVyPUSuNVEzPTVizszN	M3iwZnNCVkeHUh?=
D-502MG	NGX3U2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjGXZNKSzVyPUSuNVY6QTdizszN	MUHTRW5ITVJ?
GI-1	M1[zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33YcWlEPTB;ND6yPFI6QSEQvF2=	NGjQTGZUSU6JRWK=
NCI-H209	M4jlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rrZmlEPTB;ND6zN\|c5KM7:TR?=	NVm5[JRRW0GQR1XS
SK-OV-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTRwNEixOFkh\|ryP	MVnTRW5ITVJ?
LOUCY	NHXyTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTRwNEi0N\|Ih\|ryP	MYXTRW5ITVJ?
NCI-H69	NGntfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTGZ3VKSzVyPUSuOVE4QTNizszN	NWLEcmxyW0GQR1XS
SCC-9	M4KwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLEV49YUUN3ME20MlU{OTd{IN88US=>	M2\5VnNCVkeHUh?=
NCI-H526	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTRwNUmyPVMh\|ryP	NHfhdpBUSU6JRWK=
NCI-H2170	NGDPSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XDPGlEPTB;ND62Olc4OSEQvF2=	M2rncnNCVkeHUh?=
SR	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTRwN{CwOFgh\|ryP	MX7TRW5ITVJ?
CMK	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIq0[4NKSzVyPUSuO\|IyODFizszN	MnL3V2FPT0WU
COLO-829	NEG2fFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnz[5N5UUN3ME20Mlc4ODR\|IN88US=>	NG\NeoVUSU6JRWK=
HuO-3N1	NW\Ob4l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEe0bHJKSzVyPUSuPFMzQDFizszN	MUnTRW5ITVJ?
5637	NV70XXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGG1OIpKSzVyPUSuPVA1QDdizszN	NUPoUJJJW0GQR1XS
A253	NHLBUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rOe2lEPTB;ND65O\|cxQCEQvF2=	NWW1TYhHW0GQR1XS
NB10	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnT0TWM2OD13LkC3OFk4KM7:TR?=	MXrTRW5ITVJ?
SF539	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPWbHBKSzVyPUWuNFk6PTlizszN	NEDWUGtUSU6JRWK=
HAL-01	M4rHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Lrb2lEPTB;NT6xOFY1PSEQvF2=	NELWOmdUSU6JRWK=
MHH-ES-1	NUH6W\|loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{f6SWlEPTB;NT6xOlkzPSEQvF2=	MV3TRW5ITVJ?
DEL	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\MSndIUUN3ME21MlI4PTh{IN88US=>	MUfTRW5ITVJ?
NCI-H1299	NHL2ZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1myS2lEPTB;NT6zOVAxPyEQvF2=	NF;FV2NUSU6JRWK=
ChaGo-K-1	NIDNT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3ZZ3pCUUN3ME21MlM2OTB5IN88US=>	MXrTRW5ITVJ?
HMV-II	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTVwM{m0N{DPxE1?	Mme2V2FPT0WU
NB69	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXMfpJKSzVyPUWuN\|k3OzFizszN	MXvTRW5ITVJ?
NCI-H1882	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTVwNEOzOlQh\|ryP	NIDtRnFUSU6JRWK=
SNU-475	M4LM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDr[\|k6UUN3ME21MlQ4OTdzIN88US=>	MnHVV2FPT0WU
RXF393	MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHDVmpKSzVyPUWuOFg1QTRizszN	MVvTRW5ITVJ?
CAL-51	M{j3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPqTWM2OD13Lk[yPFU{KM7:TR?=	NGDYRVlUSU6JRWK=
SW1573	M1rjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTVwNkO1N\|Qh\|ryP	MX7TRW5ITVJ?
GCT	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS3e2o4UUN3ME21Mlc2QTJ7IN88US=>	M2jpSHNCVkeHUh?=
COR-L88	M2PXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTVTWM2OD13Lke2PFQ3KM7:TR?=	MlvoV2FPT0WU
MDA-MB-134-VI	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPiXVRTUUN3ME21Mlg4PTN4IN88US=>	MorZV2FPT0WU
NB5	MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYftNY1tUUN3ME21MlkzPDRizszN	NY[xfXlJW0GQR1XS
GMS-10	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HkTGlEPTB;NT65Olg3OSEQvF2=	NWPCcZBEW0GQR1XS
CHP-212	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjr[FBKSzVyPU[uOFgzPjdizszN	MWHTRW5ITVJ?
TE-11	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlWzTWM2OD14LkW1NVgzKM7:TR?=	MnHQV2FPT0WU
SW962	NV7sWYhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXSyZ\|lCUUN3ME22MlY2Pzd2IN88US=>	MkXnV2FPT0WU
MZ2-MEL	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTZwOEKwNVEh\|ryP	MVnTRW5ITVJ?
C-33-A	NHu5V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLSO5FlUUN3ME22MlkyPjh6IN88US=>	MljrV2FPT0WU
IGR-1	M4fJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfoTWM2OD14Lkm3PFI3KM7:TR?=	NYf1cIFoW0GQR1XS
MOLT-4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTdwMUW0NFYh\|ryP	NWHlUoNrW0GQR1XS
NCI-H1650	NGGyXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVezPJhHUUN3ME23MlI4ODR4IN88US=>	NVvwS\|djW0GQR1XS
AsPC-1	M4q4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfJfYRKSzVyPUeuNlg3ODVizszN	MoG3V2FPT0WU
SNU-C2B	NUPiNpIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXEcnFUUUN3ME23MlI6PTdzIN88US=>	NFO2PINUSU6JRWK=
MKN7	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\5bWlEPTB;Nz6zO\|I{PSEQvF2=	NUi2VWduW0GQR1XS
SW620	NVXlSIpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\BU\|hKSzVyPUeuN\|gzODVizszN	NX\N[2VRW0GQR1XS
SK-MEL-28	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fT[mlEPTB;Nz60NFc6QCEQvF2=	NUTkRo43W0GQR1XS
TE-6	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\jUYxJUUN3ME23MlQ1QTB6IN88US=>	MmT3V2FPT0WU
D-263MG	M{nqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPMVHJKSzVyPUeuOFU4PjJizszN	NWntc3k5W0GQR1XS
NCI-H1355	M172dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmS4TWM2OD15Lke3NFI6KM7:TR?=	Ml\PV2FPT0WU
DSH1	NVrPSW5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTdwN{m3OlIh\|ryP	NHzIZpNUSU6JRWK=
NCI-H460	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRThwMEC2PVQh\|ryP	MV7TRW5ITVJ?
NCI-H1563	NFz4U3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3G5ZmlEPTB;OD6wO\|UxQCEQvF2=	NXLDNZQ{W0GQR1XS
SW948	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\JSI9MUUN3ME24MlExPzR2IN88US=>	NX\MPGczW0GQR1XS
LK-2	NWH6ZnYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlyyTWM2OD16LkGyPFM{KM7:TR?=	Ml20V2FPT0WU
HT-1080	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXGT4hKSzVyPUiuNVMyPzVizszN	NV3tfZg6W0GQR1XS
NCI-H441	NUDOeXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LhU2lEPTB;OD6xPVMh\|ryP	NF3SO\|ZUSU6JRWK=
HSC-4	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWi0OoJMUUN3ME24MlI5PzJizszN	NIO2flhUSU6JRWK=
LXF-289	MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjwT2JKSzVyPUiuN\|U6PDNizszN	MkX0V2FPT0WU
MRK-nu-1	NXLvO3A{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfMOpllUUN3ME24MlM3OzB2IN88US=>	MWfTRW5ITVJ?
no-11	NUfoNnkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rC[GlEPTB;OD60O\|E{OyEQvF2=	MVvTRW5ITVJ?
SNU-387	Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVe0S\|B5UUN3ME24MlY{OjR4IN88US=>	MWXTRW5ITVJ?
Detroit562	NVP2RmF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRThwN{W0OVUh\|ryP	NFnwbYtUSU6JRWK=
SW954	NVX1emdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnyZm1JUUN3ME24Mlc3QDN{IN88US=>	MnzIV2FPT0WU
P12-ICHIKAWA	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfIc4xwUUN3ME24Mlc5QTRizszN	NFLDe5FUSU6JRWK=
TE-9	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnqyTWM2OD16LkixNFYzKM7:TR?=	MUHTRW5ITVJ?
NB13	NVfyPHo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHrTWJsUUN3ME24Mlg{Pzl4IN88US=>	M1j0NXNCVkeHUh?=
BPH-1	M1LOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHW1dGFKSzVyPUiuPFUxQDFizszN	NX7lb2h3W0GQR1XS
KMOE-2	NVLsW3B{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRThwOEe4PVIh\|ryP	NH:3VYFUSU6JRWK=
RPMI-8402	NGno[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVexO3hzUUN3ME24Mlg6QTJ4IN88US=>	MW\TRW5ITVJ?
OVCAR-3	NXnuOoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jVWGlEPTB;OD65O\|c{OiEQvF2=	MYrTRW5ITVJ?
NCI-H2196	M{LSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfsR3hKSzVyPUiuPVg3ODZizszN	M1niO3NCVkeHUh?=
MZ7-mel	NH7tcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUmzZ4hyUUN3ME25MlA{PDZizszN	M3vkdXNCVkeHUh?=
GP5d	MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfFRZZKSzVyPUmuNFY{OTNizszN	M3rXU3NCVkeHUh?=
NCI-N87	NXO4S\|ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1v3[mlEPTB;OT60OFc{OSEQvF2=	Mm\pV2FPT0WU
EW-16	NIr6T4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn0TWM2OD17LkS0PFQ5KM7:TR?=	NHjyVYFUSU6JRWK=
Calu-6	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTlwNEm3NFMh\|ryP	MmnVV2FPT0WU
LC4-1	MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnOyTWM2OD17Lk[yOVch\|ryP	M33LVHNCVkeHUh?=
CCRF-CEM	MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvlbY5KSzVyPUmuOlg4PjZizszN	NIPWW2tUSU6JRWK=
BC-1	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUSxZWYyUUN3ME25Mlc5QTlizszN	M1ru[nNCVkeHUh?=
NCI-SNU-16	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXNN4hKSzVyPUmuO\|k1QTVizszN	NIGwdndUSU6JRWK=
NCI-H28	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\kTWM2OD17Lki0PVM{KM7:TR?=	M1;RXXNCVkeHUh?=
SBC-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTFyLkC3NkDPxE1?	Ml;YV2FPT0WU
TUR	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zaW2lEPTB;MUCuNVY2PyEQvF2=	Ml3wV2FPT0WU
MDA-MB-231	M2[zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDXTWM2OD1zMD6yNVE1KM7:TR?=	NXThWINjW0GQR1XS
C3A	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnBZVRKSzVyPUGwMlMyPzlizszN	M2rD[3NCVkeHUh?=
SW1990	NFP3NoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2m2cmlEPTB;MUCuN\|I5KM7:TR?=	NILHbINUSU6JRWK=
NCI-H1993	NGLP[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTsUZVKSzVyPUGwMlU3QTNizszN	NYfre45PW0GQR1XS
SK-CO-1	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjUO4tKSzVyPUGwMlc4PyEQvF2=	MXrTRW5ITVJ?
OAW-28	NIfrTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHCZ2tKSzVyPUGwMlk5QDhizszN	MWDTRW5ITVJ?
HN	NUP5W\|BlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTFzLkGxN\|Eh\|ryP	NF7adlhUSU6JRWK=
NCI-H1304	NUXseo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTFzLkG1O\|Yh\|ryP	NX;mSmxYW0GQR1XS
Daoy	MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLaVoNKSzVyPUGxMlQ{OzZizszN	NIn3fWJUSU6JRWK=
VA-ES-BJ	NYjJTndjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj2XWhHUUN3ME2xNU44OTl3IN88US=>	MmX6V2FPT0WU
MCF7	NXT6cIR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XlSWlEPTB;MUGuPFEzPiEQvF2=	Mor3V2FPT0WU
VM-CUB-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHL2b25KSzVyPUGxMlkxQTFizszN	MXvTRW5ITVJ?
IPC-298	NFHJXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfHTWM2OD1zMT65N\|g{KM7:TR?=	NFHNWplUSU6JRWK=
NCI-H2126	M2P4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUS5b45MUUN3ME2xNk4xOjF6IN88US=>	MVnTRW5ITVJ?
OVCAR-8	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLi[YpJUUN3ME2xNk4yOTRzIN88US=>	MnjOV2FPT0WU
SJRH30	MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHUWJNoUUN3ME2xNk4zOjl7IN88US=>	MmjlV2FPT0WU
DMS-53	M4e3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlm0TWM2OD1zMj6yOlQ6KM7:TR?=	MXXTRW5ITVJ?
NCI-H322M	NVfXTmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrXSZFiUUN3ME2xNk4{OzV5IN88US=>	MkTOV2FPT0WU
RVH-421	M2T4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTF{LkS5NFQh\|ryP	M2\yZXNCVkeHUh?=
Raji	NULKUmFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XkVmlEPTB;MUKuOlE1KM7:TR?=	MUDTRW5ITVJ?
MDA-MB-415	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofuTWM2OD1zMj62OFQ1KM7:TR?=	NVPkfpdiW0GQR1XS
EFE-184	M3flPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTF{LkexNFYh\|ryP	NWPke3BYW0GQR1XS
BFTC-909	NVW2dpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHVTWM2OD1zMj65NlQ4KM7:TR?=	MX3TRW5ITVJ?
BHY	NIHtZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknlTWM2OD1zMz6zN\|kh\|ryP	NXX3fod5W0GQR1XS
YKG-1	M3PIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTZdJZLUUN3ME2xN{4{PzR7IN88US=>	NVrlZ4VSW0GQR1XS
EW-3	NHjSfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTTcGVnUUN3ME2xN{44OTZ\|IN88US=>	NEj1dIRUSU6JRWK=
HCC1143	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTF\|Lke0N\|ch\|ryP	MlGxV2FPT0WU
REH	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vGbmlEPTB;MUOuPFk5OiEQvF2=	MkXsV2FPT0WU
CESS	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLiTWM2OD1zMz65OFg6KM7:TR?=	MVjTRW5ITVJ?
EFM-19	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfBbnRKSzVyPUG0MlEyOTJizszN	NVjxUoxRW0GQR1XS
U031	M1z0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LLeWlEPTB;MUSuOFA5PSEQvF2=	MYPTRW5ITVJ?
ES1	M1GweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVn3UZp7UUN3ME2xOE41QDVzIN88US=>	NY\wXJM{W0GQR1XS
HSC-3	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInwbJhKSzVyPUG0MlYzOTVizszN	NF[yUIRUSU6JRWK=
LOXIMVI	M1\pdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTF2LkewOlgh\|ryP	MmrrV2FPT0WU
A388	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3i3[mlEPTB;MUSuO\|U2PiEQvF2=	Mlr6V2FPT0WU
KP-N-YS	NHvH[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTsTWM2OD1zND63O\|Mh\|ryP	NEXtcHVUSU6JRWK=
Capan-2	Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTF2Lke4OkDPxE1?	NETJOJpUSU6JRWK=
SKG-IIIa	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDIWJFZUUN3ME2xOE45QDZ{IN88US=>	NV[zb3JJW0GQR1XS
HEL	NFvmeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLWcJZKSzVyPUG0Mlg6QTdizszN	NUm1TnlrW0GQR1XS
BEN	NYTZRZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTF2Lkm3OlYh\|ryP	NWDzN3ZtW0GQR1XS
MC116	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTF3LkG1PVkh\|ryP	NFTrUlhUSU6JRWK=
IGROV-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfSc\|NLUUN3ME2xOU4zOzF5IN88US=>	MYTTRW5ITVJ?
NCI-H1648	NVHReIE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTF3LkWzNFUh\|ryP	M2fRb3NCVkeHUh?=
ABC-1	NI\BRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTF3LkiwN\|Mh\|ryP	NHPpOGdUSU6JRWK=
EW-18	NUTrTml{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nYO2lEPTB;MUWuPVk4QSEQvF2=	MkO2V2FPT0WU
BC-3	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF4LkC1OlIh\|ryP	Mkn5V2FPT0WU
NCI-H1437	MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TpXGlEPTB;MU[uNFY3PyEQvF2=	MlTjV2FPT0WU
SCC-15	M324eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLtTWM2OD1zNj6yPFI2KM7:TR?=	MV3TRW5ITVJ?
TT	NXPiUoJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLiTWM2OD1zNj61PFg5KM7:TR?=	NH7peo5USU6JRWK=
KINGS-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1iyXWlEPTB;MU[uPFI4OyEQvF2=	NYTMSXN{W0GQR1XS
C32	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFX0b2FKSzVyPUG2Mlk4OTdizszN	MmrIV2FPT0WU
SBC-5	M{jTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjZO\|dKSzVyPUG3MlE1PzlizszN	MlvlV2FPT0WU
NB1	M2CzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXUVWJ5UUN3ME2xO{4{OTh6IN88US=>	MkPtV2FPT0WU
EB-3	NV;tOYh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTF5LkW3OkDPxE1?	MWfTRW5ITVJ?
NCI-H748	NGPtcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlO4TWM2OD1zNz63NFM2KM7:TR?=	MWPTRW5ITVJ?
IST-SL1	M1;hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjGNFZKSzVyPUG3Mlc2OjZizszN	NFi2NoNUSU6JRWK=
WM-115	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTF5LkiwPFUh\|ryP	Mm\CV2FPT0WU
NCI-H226	NFS3ZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL5dG1QUUN3ME2xO{46PTR4IN88US=>	NV\YTIJSW0GQR1XS
CAL-33	NVLPNZBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXSS4dKSzVyPUG4MlI4QDFizszN	Mlz2V2FPT0WU
SCC-4	NFv5[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrQVlR3UUN3ME2xPE4{OjJ7IN88US=>	NYSwOpRuW0GQR1XS
RMG-I	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfITWM2OD1zOD62PVQ4KM7:TR?=	NFqyfmlUSU6JRWK=
KOSC-2	NF3WVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\Oc2lEPTB;MUiuO\|c1PiEQvF2=	MX7TRW5ITVJ?
A2058	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTITWM2OD1zOD64NlU2KM7:TR?=	MYrTRW5ITVJ?
HCC70	M3naWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTDd4J3UUN3ME2xPU4{QDl2IN88US=>	NXzpcG5pW0GQR1XS
C2BBe1	NHPTbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3y2dGlEPTB;MUmuOFE1QCEQvF2=	MnLFV2FPT0WU
NCI-H650	NXfObpRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTGR3ZOUUN3ME2xPU42QDl7IN88US=>	MX3TRW5ITVJ?
CAL-72	NETafZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\CXFRKSzVyPUG5MlY4OzdizszN	MV3TRW5ITVJ?
L-363	NEjUOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7nS3hKSzVyPUKwMlAzOTJizszN	NF7vPGVUSU6JRWK=
SNU-423	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTJyLkGwOFMh\|ryP	MXXTRW5ITVJ?
PLC-PRF-5	MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2exUGlEPTB;MkCuN\|kxPiEQvF2=	M{jrU3NCVkeHUh?=
SW1463	M{XEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTJyLkS1NlUh\|ryP	MmnGV2FPT0WU
769-P	M{PJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3j[mxKSzVyPUKwMlY4PjlizszN	NXi5S5l4W0GQR1XS
DMS-79	NInMVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LJN2lEPTB;MkCuPFQ6KM7:TR?=	MlfiV2FPT0WU
Saos-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1m3VmlEPTB;MkCuPVU2PiEQvF2=	MmLkV2FPT0WU
CHP-126	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHVcnk4UUN3ME2yNU41PDZ{IN88US=>	NFfYOmdUSU6JRWK=
SW837	MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHnSZN4UUN3ME2yNU41QTN7IN88US=>	M3X6fXNCVkeHUh?=
SHP-77	NVny[ZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DnNWlEPTB;MkGuOlEzOiEQvF2=	MlTEV2FPT0WU
DB	NEXvUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LwbWlEPTB;MkGuOlE1OiEQvF2=	M{Hj[3NCVkeHUh?=
ES5	M3HKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmraTWM2OD1{MT62PFY1KM7:TR?=	NUfuSoRXW0GQR1XS
COR-L23	M1rSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TXVWlEPTB;MkGuPFA2OSEQvF2=	MV3TRW5ITVJ?
KU-19-19	M{Sycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXqNY1KSzVyPUKxMlg6QDJizszN	M1jWfXNCVkeHUh?=
T84	NVixbJJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPwUY9KSzVyPUKxMlk5OTlizszN	MmjFV2FPT0WU
NCI-H630	NXPT[ZhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHSS5FKSzVyPUKyMlU{PjNizszN	M2j3RXNCVkeHUh?=
LU-165	M{\xbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2f5W2lEPTB;MkKuOVU1KM7:TR?=	NV;5fJpzW0GQR1XS
COLO-792	NVXOPHc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojQTWM2OD1{Mj63NVEyKM7:TR?=	Mn3LV2FPT0WU
CAL-62	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\JZYFKSzVyPUKyMlc2OTdizszN	Mn\zV2FPT0WU
HCE-T	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTJ{Lki2NFYh\|ryP	MX\TRW5ITVJ?
BB65-RCC	NVLLO3N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDxVHZKSzVyPUKzMlA{PDRizszN	M{nPNXNCVkeHUh?=
SiHa	NGPwdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYK0fYhnUUN3ME2yN{4{QTZ6IN88US=>	MlnQV2FPT0WU
NCI-H2081	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTJ2LkC2OFEh\|ryP	NHPMO29USU6JRWK=
U251	M2nDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;YNotKUUN3ME2yOE4xPjZ6IN88US=>	NVH5fZNjW0GQR1XS
LoVo	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTJ2LkmyPFIh\|ryP	NYnpbldCW0GQR1XS
GCIY	NH\JdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLUO\|NrUUN3ME2yOU4zQDd5IN88US=>	M{fBNXNCVkeHUh?=
NUGC-3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2X6XmlEPTB;MkWuN\|MyPiEQvF2=	MmHYV2FPT0WU
LNCaP-Clone-FGC	NF3STIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjrNHFKSzVyPUK1MlM1QThizszN	M{f4R3NCVkeHUh?=
PA-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTJ3Lk[4N\|Mh\|ryP	MnP6V2FPT0WU
OE33	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDCdXlVUUN3ME2yOU43QDV\|IN88US=>	MkDHV2FPT0WU
HT-29	NHq4d3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHYTWM2OD1{NT63PFc6KM7:TR?=	MlG5V2FPT0WU
RCM-1	NFi0WnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDmSWFKSzVyPUK1Mlk3PTZizszN	NGHiboNUSU6JRWK=
NCI-H1522	NEK0eHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPxSFRKUUN3ME2yOU46QTFzIN88US=>	NXz4bpNSW0GQR1XS
LB373-MEL-D	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;2TJlKSzVyPUK2MlE4ODhizszN	NWHUSYZ[W0GQR1XS
NCI-H1436	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXrdYpSUUN3ME2yOk4zPzN6IN88US=>	MWfTRW5ITVJ?
COLO-824	NXPDXHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTJ4LkSwNFIh\|ryP	MoK0V2FPT0WU
CP50-MEL-B	NVXxWVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnVTWM2OD1{Nj61Olc2KM7:TR?=	M3vHTnNCVkeHUh?=
EGI-1	M3z6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTJ5LkK2PVgh\|ryP	MUTTRW5ITVJ?
LAN-6	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTkdVJXUUN3ME2yO{4{PTl6IN88US=>	NFrnSFdUSU6JRWK=
GAK	NWfTfXR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTJ5LkSyNlUh\|ryP	NVHwOm9mW0GQR1XS
MDA-MB-175-VII	NVHS[4ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzTU5UxUUN3ME2yO{42ODV\|IN88US=>	MVTTRW5ITVJ?
JVM-2	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvHTWM2OD1{Nz62OlIzKM7:TR?=	M4fXZXNCVkeHUh?=
UACC-257	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\HUYVKSzVyPUK3MlY5PzhizszN	NFHLZ2hUSU6JRWK=
SW1783	NHrFSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3aWZdMUUN3ME2yO{44Pzh\|IN88US=>	NE\NTYFUSU6JRWK=
HT-3	M3H3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXtTWM2OD1{OD6yNVY3KM7:TR?=	NXHuWXZOW0GQR1XS
RL	MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7VRXRLUUN3ME2yPE42QTFzIN88US=>	NHvPeodUSU6JRWK=
TK10	M3\qNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHK5SFlKSzVyPUK4MlY2OzVizszN	M4n4[HNCVkeHUh?=
HT55	NWHBVYlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3njSmlEPTB;MkmuNFU3PSEQvF2=	NYPBS3QxW0GQR1XS
BT-20	M2SwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Lu[mlEPTB;MkmuNFU5PiEQvF2=	M1\aTHNCVkeHUh?=
TGBC24TKB	NXjZeXZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfTVpA6UUN3ME2yPU4yQDNzIN88US=>	NGDReHJUSU6JRWK=
HSC-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF2zWYZKSzVyPUK5MlMxODFizszN	MYXTRW5ITVJ?
COLO-205	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTrTWM2OD1{OT6zPVQ1KM7:TR?=	NYfWPGpyW0GQR1XS
GT3TKB	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXaZVZuUUN3ME2yPU43QDd5IN88US=>	NHnERmVUSU6JRWK=
T47D	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XhNmlEPTB;MkmuPFU5OiEQvF2=	M1\MOHNCVkeHUh?=
OMC-1	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37HVWlEPTB;M{CuNVkyQSEQvF2=	NGflPJBUSU6JRWK=
PFSK-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M120PWlEPTB;M{GuNlY2QSEQvF2=	NIK4e3BUSU6JRWK=
JEG-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\XTWM2OD1\|MT6zOVYyKM7:TR?=	Ml3hV2FPT0WU
RD	M1[zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDITWM2OD1\|MT61NVE2KM7:TR?=	MWHTRW5ITVJ?
NCI-H64	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTqdWpHUUN3ME2zNk41OTd7IN88US=>	M3\nbHNCVkeHUh?=
DMS-114	Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoftTWM2OD1\|Mj60NVgzKM7:TR?=	NIC4S5lUSU6JRWK=
NCI-H661	NEXxeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3O1XGlEPTB;M{KuOlUxOSEQvF2=	NEC2V45USU6JRWK=
CAL-148	NXzKcXoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nVTWlEPTB;M{KuOlY3PSEQvF2=	MYXTRW5ITVJ?
HuP-T3	Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHFe4V5UUN3ME2zNk46OzN6IN88US=>	MWDTRW5ITVJ?
ES4	NETtdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfKcHZKSzVyPUOzMlE4ODVizszN	NVL2dW8zW0GQR1XS
Ca9-22	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPBTWM2OD1\|Mz60OlAyKM7:TR?=	M{LuTXNCVkeHUh?=
LP-1	M2TwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTN2LkC5JO69VQ>?	MYXTRW5ITVJ?
AU565	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTN2LkWwOlkh\|ryP	M1;YSnNCVkeHUh?=
MDA-MB-453	NHO2Tm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\aW3JKSzVyPUO1MlE1OjZizszN	NYXkWoR4W0GQR1XS
SNU-C1	NX3K[Yw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHKPZFKSzVyPUO1MlE4OSEQvF2=	MoXzV2FPT0WU
SW13	NWfJO286T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfkU3o4UUN3ME2zOU41ODd4IN88US=>	M3XlWXNCVkeHUh?=
NCI-H2122	NW\xPJRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\3NYEyUUN3ME2zOU42PTl6IN88US=>	M1rIZXNCVkeHUh?=
NCI-H1395	M4PnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\0e3JKSzVyPUO1MlY3QTFizszN	MUHTRW5ITVJ?
J-RT3-T3-5	MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnRNnBWUUN3ME2zOk4xOjl2IN88US=>	MWTTRW5ITVJ?
COR-L279	NYH0Wm1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTN4LkG5PFEh\|ryP	MoPiV2FPT0WU
ATN-1	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mln6TWM2OD1\|Nj64OVE3KM7:TR?=	NVPYdnRyW0GQR1XS
HCC2998	NXL6T2E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\hWFNFUUN3ME2zOk45PTdzIN88US=>	MVXTRW5ITVJ?
UM-UC-3	MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfqNHhKSzVyPUO2Mlg3PzVizszN	M{XCN3NCVkeHUh?=
DV-90	NXfrR2pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHf3bFhKSzVyPUO2MlkxPjdizszN	MmnWV2FPT0WU
ES8	NG\x[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH4Z45{UUN3ME2zOk46OzF6IN88US=>	MlTMV2FPT0WU
YAPC	M4f3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTN4Lkm2OVQh\|ryP	MVnTRW5ITVJ?
HCC1599	M1jye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vpdmlEPTB;M{euNVYyQCEQvF2=	MVrTRW5ITVJ?
UMC-11	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTN5LkK1NFMh\|ryP	M{X0TXNCVkeHUh?=
THP-1	NEfHTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTN5LkK4Olgh\|ryP	NELQdW1USU6JRWK=
OCUB-M	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfiTWM2OD1\|Nz6yPFkyKM7:TR?=	NIjSPHVUSU6JRWK=
NCI-H1693	MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnhXZVKSzVyPUO3MlMzOzNizszN	NImzUIFUSU6JRWK=
NCI-H345	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;YWWlEPTB;M{euN\|YzPCEQvF2=	NHnpSHlUSU6JRWK=
COLO-800	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnYSHNiUUN3ME2zO{42PjdizszN	M4PYZ3NCVkeHUh?=
COLO-320-HSR	Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTN6LkO0PVIh\|ryP	NEC1Rm5USU6JRWK=
NCI-H596	MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHO[m1KSzVyPUO4MlQ1QDlizszN	MVXTRW5ITVJ?
NCI-H187	NV;JR4hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\pTWM2OD1\|OD63N\|Q1KM7:TR?=	NGPITo1USU6JRWK=
ECC4	NETSVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nDXGlEPTB;M{muNFgyPCEQvF2=	M2ra[nNCVkeHUh?=
KP-4	MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTN7LkGyN\|Uh\|ryP	NHX0VYFUSU6JRWK=
NCI-H2227	M3XqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTN7LkO5OFkh\|ryP	M{nlfHNCVkeHUh?=
22RV1	NYHNfVJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2iyfGlEPTB;M{muPFM6QCEQvF2=	Ml3VV2FPT0WU
SAS	NI\rOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHyN5lKSzVyPUSwMlA6PiEQvF2=	NY\PcXI4W0GQR1XS
PANC-10-05	NIPpTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PsOWlEPTB;NECuNVgzQCEQvF2=	MYDTRW5ITVJ?
MDA-MB-468	NHixemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTRyLkWzOFYh\|ryP	NXHScm1uW0GQR1XS
RPMI-7951	MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DrTmlEPTB;NEGuNlA4PSEQvF2=	MkW1V2FPT0WU
BB49-HNC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTRzLkKxO\|kh\|ryP	NVftPIM3W0GQR1XS
23132-87	NH;aW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HXNGlEPTB;NEGuNlc{OiEQvF2=	M1LjUXNCVkeHUh?=
HCC1569	NWLUdW9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;LTWM2OD12MT6yPFg2KM7:TR?=	M{PhSXNCVkeHUh?=
CP66-MEL	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Xmb2lEPTB;NEKuNVg5PiEQvF2=	M3z1bXNCVkeHUh?=
K-562	M1X3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPQOW1QUUN3ME20Nk4zQDV2IN88US=>	M2i0eXNCVkeHUh?=
OCI-AML2	M1;CSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXFTW9KSzVyPUSyMlg6PzRizszN	NXPqZ3E5W0GQR1XS
SW756	M{nCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTR\|LkCzPFgh\|ryP	M1jUUHNCVkeHUh?=
M14	NIK1V4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITyTnRKSzVyPUSzMlMyQDlizszN	NXf4N\|dwW0GQR1XS
NCI-H1623	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXi3W\|U4UUN3ME20N{41PjRizszN	NYrDNWZPW0GQR1XS
KNS-81-FD	M3Tq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH72e5VKSzVyPUSzMlc3OiEQvF2=	MYDTRW5ITVJ?
TGBC1TKB	MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LPNmlEPTB;NEOuPVA6QSEQvF2=	NX\UVVNFW0GQR1XS
RERF-LC-MS	NXHTb41uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTVTWM2OD12Mz65NlgyKM7:TR?=	NEXTeWlUSU6JRWK=
PC-3	M3vpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\uV4JCUUN3ME20OE41OzR5IN88US=>	NYKxdnFiW0GQR1XS
HuP-T4	NX3DbHJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HvR2lEPTB;NESuOFQ4PCEQvF2=	M2DIbXNCVkeHUh?=
NCI-H510A	NXXYO\|Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFq3cJVKSzVyPUS0MlcxQCEQvF2=	NVj0NnpRW0GQR1XS
LB2518-MEL	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfDSmZGUUN3ME20OE44QTN5IN88US=>	MlTFV2FPT0WU
TE-5	M3TLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTR3Lkm1PFEh\|ryP	M4LofnNCVkeHUh?=
EW-24	M{PpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;GdmtKSzVyPUS2MlE4OjNizszN	MXrTRW5ITVJ?
LB647-SCLC	NWHTTG4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTR4LkKxOVUh\|ryP	M4HlZ3NCVkeHUh?=
NCI-H524	NWnZZpZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTR4LkexPFUh\|ryP	MXnTRW5ITVJ?
EW-11	M4HVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTjTWM2OD12Nj65N\|c{KM7:TR?=	NUPYV3h1W0GQR1XS
KALS-1	NG\SXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfsS28{UUN3ME20O{4zODZ4IN88US=>	MnjOV2FPT0WU
BT-474	M37je2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWKwb21zUUN3ME20O{41OjF4IN88US=>	NFvtcVZUSU6JRWK=
SK-N-AS	NFPYcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILlRY5KSzVyPUS3Mlg5QCEQvF2=	M{PUVnNCVkeHUh?=
HCC2157	NXrUeWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTR6LkC3OkDPxE1?	NYfFO\|hXW0GQR1XS
HCC1954	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnsRYtKSzVyPUS4MlE4ODRizszN	MoLUV2FPT0WU
FADU	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFntelBKSzVyPUS4MlMxOzFizszN	NFLhfWxUSU6JRWK=
S-117	NWnRSItHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHnb4lZUUN3ME20PE4{QDF3IN88US=>	M2fs[3NCVkeHUh?=
LS-1034	NX7ZVFE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFn0SZpKSzVyPUS4MlcxPjdizszN	MoXiV2FPT0WU
CAMA-1	NG\qbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTR7LkW1OFMh\|ryP	MlHyV2FPT0WU
LU-134-A	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTIe29CUUN3ME20PU45ODh3IN88US=>	Mkj1V2FPT0WU
NCI-H1838	NHfWO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPqVYNrUUN3ME20PU45ODh5IN88US=>	NVy4RYprW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

体内試験

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

お薦めの試験操作（参考用のみ）

キナーゼ試験：^[1]	- 合併 Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
細胞試験： ^[2]	- 合併細胞株： Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl 濃度： 0-625 nM 反応時間： 72 hours 実験の流れ： Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (参考用のみ)
動物試験：^[1]	- 合併動物モデル： Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I 製剤： Dissolved in 25 mM citrate buffer, pH 2.75 投薬量： 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I 投与方法： Oral gavage once daily (参考用のみ)

参考

- 合併

溶解度 (25°C)

体外	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 1% CMC Na 混合させたのち直ちに使用することを推奨します。	30mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Ponatinib (AP24534) SDFをダウンロードする

分子量	532.56
化学式	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
保管	3年-20°C粉
保管	2 years-80°C in solvent
別名	N/A
Smiles	CN1CCN(CC1)CC2=C(C=C(NC(=O)C3=CC(=C(C)C=C3)C#CC4=CN=C5C=CC=N[N]45)C=C2)C(F)(F)F

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04070443	Not yet recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	October 1 2019	Phase 2
NCT03934372	Not yet recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	October 25 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
回答：
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Ablシグナル伝達経路

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

相関Bcr-Abl製品

PX-478 2HCl

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Defactinib (VS-6063)

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib Mesylate (STI571)

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Features:A conformational control inhibitor of Abl1 and T315I Abl1.

研究分野別

製品類型

Ponatinib (AP24534)

文献中Selleckの製品使用例(83)

製品安全説明書

Bcr-Abl阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Ponatinib (AP24534) SDFをダウンロードする

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技術サポート

よくある質問（FAQ）

Bcr-Ablシグナル伝達経路

Bcr-Abl Inhibitors with Unique Features

相関Bcr-Abl製品